Global Cell Therapy Technologies Market is expected to grow at a CAGR of 16.81% during the forecast period from 2018-2025
A new research report published by Fior Markets with the title Global Cell Therapy Technologies Market by Product (Consumables, Equipment, Software), Cell Type (Human Stem & Differentiated, Animal), Process, End User, and Region and Global Forecast 2018-2025.
As per the report, the global cell therapy technologies market is expected to grow from USD 11.2 Billion in 2017 to USD 34.41 Billion by 2025 at a CAGR of 16.81% during the forecast period from 2018-2025. North America is expected to dominate the market during the forecast period. Due to advanced healthcare infrastructure in the region and high burden of chronic diseases and increasing R&D activities in the pharmaceutical and biotechnology industries.
DOWNLOAD FREE SAMPLE REPORT: https://www.fiormarkets.com/report-detail/376050/request-sample
Key players operating in the market are Beckman Coulter, Becton, Dickinson and Company, GE Healthcare, Lonza, Merck KGaA, Miltenyi Biotec, STEMCELL Technologies, Inc., Terumo BCT, and Thermo Fisher Scientific, PHARMICELL Co. Ltd, ANTEROGEN.CO.LTD., Novartis AG, GlaxoSmithKline plc, CELGENE CORPORATION, Bone Therapeutics, Cell Therapies, Celyad, Regen BioPharma, Cellular Therapeutics Ltd, TxCell, Advancells and others. Key players active in the market are involved in collaborative agreements and expansion to bolster the growth of the market. For instance, in 2018, Sartorius offered current and future Lonza media and buffers as part of its extensive portfolio of products for cell-based development and manufacturing.
The product segment is classified into consumables, equipment, and systems & software. The consumables segment is dominated the market and was valued around USD 4.59 billion in 2017. Factors such as increasing investments by companies to develop advanced products are contributing to the growth of the cell therapy consumables market. Process segment is divided into cell processing cell preservation, distribution, and handling and process monitoring and quality control. Cell type segment is classified into human cells and animal cells. The human cells segment is expected to grow with the highest CAGR in the forecast period. The rising adoption of human cells over animal cells for cell therapeutics research and technological advancements are the key factors driving the growth of this segment. End user segment is bifurcated into life science research companies and research institutes. The life science research companies segment is dominating and held the largest share of 2017. The growth can be attributed to the high adoption of advanced instruments in cell-based experiments and cancer research as well as the increasing number of R&D facilities globally.
Regulatory bodies providing support to innovators for novel and effective solutions for patients as driving the growth of the market. In addition, increasing investments by major players strengthening the market. High cost of cell-based research may restrict the growth of the market. However, healthcare industries are making significant use of stem cells for treatment of patients with cancer, blood disorders, and immune-related disorders.
About the report:
The global market is analysed on the basis of value (USD Billion), volume (K Units), export (K Units), and import (K Units). All the segments have been analyzed on global, regional and country basis. The study includes the analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porter’s five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.
Customization of the Report:
The report can be customized as per client requirements. For further queries, you can contact us on firstname.lastname@example.org or +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.
- CDN Newswire